The “Fit for Growth” strategy that Biogen, Inc. CEO Christopher Viehbacher and his executive team put into place last year to trim $1bn in costs and reinvest the savings into research and development as well as business development seems to finally be paying off. The firm reported product sales growth for the second quarter, which the company has been seeking for years while revenue from its multiple sclerosis portfolio has largely been in decline.
Key Takeaways
-
Biogen delivered flat total revenue and increased product revenue in the second quarter and increased its full-year guidance slightly, for the first positive quarter in years.
While both products are rising from a small base, sales of the Eisai Co., Ltd.-partnered anti-amyloid antibody Leqembi (lecanemab)...






